诊断前循环炎症生物标志物对乳腺癌生存的预后作用：来自 EPIC 队列研究的证据。
Prognostic role of pre-diagnostic circulating inflammatory biomarkers in breast cancer survival: evidence from the EPIC cohort study.
发表日期：2024 Sep 28
作者：
Carlota Castro-Espin, Manon Cairat, Anne-Sophie Navionis, Christina C Dahm, Christian S Antoniussen, Anne Tjønneland, Lene Mellemkjær, Francesca Romana Mancini, Mariem Hajji-Louati, Gianluca Severi, Charlotte Le Cornet, Rudolf Kaaks, Matthias B Schulze, Giovanna Masala, Claudia Agnoli, Carlotta Sacerdote, Marta Crous-Bou, Maria-Jose Sánchez, Pilar Amiano, María-Dolores Chirlaque, Marcela Guevara, Karl Smith-Byrne, Alicia K Heath, Sofia Christakoudi, Marc J Gunter, Sabina Rinaldi, Antonio Agudo, Laure Dossus
来源：
BRITISH JOURNAL OF CANCER
摘要：
炎症影响肿瘤进展和癌症预后，但其在乳腺癌 (BC) 发生前的作用及其预后意义仍无定论。我们研究了 EPIC 研究中 1538 名 BC 女性的诊断前血浆炎症生物标志物。 Cox 比例风险模型评估了它们与全因死亡率和 BC 特异性死亡率的关系，并调整了肿瘤特征和生活方式因素。诊断后的 7 年随访中，229 名女性死亡，其中 163 人死于 BC。 IL-6 水平升高与全因死亡风险增加相关（HR1-SD 1.25，95% CI 1.07-1.47）。在绝经后，IL-6 与较高的全因死亡率（HR1-SD 1.41，95% CI 1.18-1.69）和 BC 特异性死亡率（HR1-SD 1.31，95% CI 1.03-1.66）相关。绝经后） < 0.05），而 IL-10 和 TNFα 仅与全因死亡率相关（HR1-SD 1.19，95% CI 1.02-1.40 和 HR1-SD 1.28，95% CI 1.06-1.56）。在 ER PR 中，IL-10 与全因死亡率和 BC 特异性死亡率相关（HR1-SD 1.35，95% CI 1.10-1.65 和 HR1-SD 1.42 95% CI 1.08-1.86），而 TNF-α 与HER2- 的全因死亡率（HR1-SD 1.31，95% CI 1.07-1.61）。炎症评分预测较高的全因死亡率，尤其是绝经后女性（HR1-SD 1.30，95% CI 1.07-1.58）。较高的诊断前 IL-6 水平表明 BC 幸存者的长期生存较差。在绝经后幸存者中，IL-6、IL-10 和 TNFα 升高以及炎症评分似乎可以预测全因死亡率。© 2024。作者。
Inflammation influences tumour progression and cancer prognosis, but its role preceding breast cancer (BC) and its prognostic implications remain inconclusive.We studied pre-diagnostic plasma inflammatory biomarkers in 1538 women with BC from the EPIC study. Cox proportional hazards models assessed their relationship with all-cause and BC-specific mortality, adjusting for tumour characteristics and lifestyle factors.Over a 7-year follow-up after diagnosis, 229 women died, 163 from BC. Elevated IL-6 levels were associated with increased all-cause mortality risk (HR1-SD 1.25, 95% CI 1.07-1.47). Among postmenopausal, IL-6 was associated with higher all-cause (HR1-SD 1.41, 95% CI 1.18-1.69) and BC-specific mortality (HR1-SD 1.31, 95% CI 1.03-1.66), (PHeterogeneity (pre/postmenopausal) < 0.05 for both), while IL-10 and TNFα were associated with all-cause mortality only (HR1-SD 1.19, 95% CI 1.02-1.40 and HR1-SD 1.28, 95% CI 1.06-1.56). Among ER+PR+, IL-10 was associated with all-cause and BC-specific mortality (HR1-SD 1.35, 95% CI 1.10-1.65 and HR1-SD 1.42 95% CI 1.08-1.86), while TNF-α was associated with all-cause mortality in HER2- (HR1-SD 1.31, 95% CI 1.07-1.61). An inflammatory score predicted higher all-cause mortality, especially in postmenopausal women (HR1-SD 1.30, 95% CI 1.07-1.58).Higher pre-diagnosis IL-6 levels suggest poorer long-term survival among BC survivors. In postmenopausal survivors, elevated IL-6, IL-10, and TNFα and inflammatory scores seem to predict all-cause mortality.© 2024. The Author(s).